You just read:

Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America

News provided by

Abide Therapeutics, Inc.

18 Apr, 2017, 08:37 ET